Rare Disease Biotechs Avrobio, Eidos Therapeutics File for IPOs

Avrobio and Eidos Therapeutics, rare disease drug developers on opposite sides of the country, have filed for initial public offerings, each company aiming to raise cash to finance more clinical tests of its lead drug.